Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 16, 2017, Pages 4213-4218

  Echigoya, Yusuke ^a   Nakamura, Akinori ^b,c   Nagata, Tetsuya ^b   Urasawa, Nobuyuki ^b,d   Lim, Kenji Rowel Q ^a   Trieu, Nhu ^a   Panesar, Dharminder ^a   Kuraoka, Mutsuki ^b   Moulton, Hong M ^e   Saito, Takashi ^b   Aoki, Yoshitsugu ^b   Iversen, Patrick ^f   Sazani, Peter ^f   Kole, Ryszard ^f   Maruyama, Rika ^a   Partridge, Terry ^g,h   Takeda, Shin'ichi ^b   Yokota, Toshifumi ^a,i  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NAGANO RED CROSS HOSPITAL   (Japan)

^e OREGON STATE UNIVERSITY   (United States)

^f AVI BIOPHARMA INC   (United States)

^g CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^h GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

ⁱ Friends of Garrett Cumming Research   (Canada)

Author keywords

Cardiac Purkinje fibers; Duchenne muscular dystrophy; Dystrophic dog model; Exon skipping; Peptide conjugated morpholinos

Indexed keywords

CELL PENETRATING PEPTIDE; DYSTROPHIN; MORPHOLINO OLIGONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANINE MODEL; CARDIAC MUSCLE; CELL VACUOLE; DIASTOLE; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; HEART; HEART CONDUCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE CONTRACTILITY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PURKINJE FIBER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; SYMPTOM; SYSTEMIC THERAPY; SYSTOLE; WESTERN BLOTTING; ANIMAL; ANIMAL MUSCULAR DYSTROPHY; CARDIOMYOPATHY; COMPLICATION; DISEASE MODEL; DOG; EXON; FEMALE; GENE THERAPY; GENETICS; MALE; METABOLISM; PATHOLOGY;

ANIMALS; CARDIOMYOPATHIES; CELL-PENETRATING PEPTIDES; DISEASE MODELS, ANIMAL; DOGS; DYSTROPHIN; EXONS; FEMALE; GENETIC THERAPY; MALE; MORPHOLINOS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 85017584647     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1613203114     Document Type: Article

References (45)

1. Flanigan KM (2014) Duchenne and Becker muscular dystrophies. Neurol Clin 32(3): 671-688, viii.
2. Koenig M, et al. (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50(3):509-517.
3. Mendell JR, et al.; Eteplirsen Study Group and Telethon Foundation DMD Italian Network (2016) Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 79(2):257-271.
4. Echigoya Y, Mouly V, Garcia L, Yokota T, Duddy W (2015) In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy. PLoS One 10(3):e0120058.
5. Béroud C, et al. (2007) Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat 28(2):196-202.
6. Nakamura A, et al. (2016) Deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy. J Hum Genet 61(7):663-667.
7. Aartsma-Rus A, et al. (2009) Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30(3):293-299.
8. Echigoya Y, Yokota T (2014) Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides. Nucleic Acid Ther 24(1):57-68.
9. Aoki Y, et al. (2012) Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci USA 109(34):13763-13768.
10. Yokota T, et al. (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65(6):667-676.
11. Aoki Y, et al. (2010) In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther 18(11): 1995-2005.
12. Yu X, Bao B, Echigoya Y, Yokota T (2015) Dystrophin-deficient large animal models: Translational research and exon skipping. Am J Transl Res 7(8):1314-1331.
13. Alter J, et al. (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12(2): 175-177.
14. Kornegay JN, et al. (2010) Widespread muscle expression of an AAV9 human minidystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther 18(8):1501-1508.
15. Yue Y, et al. (2015) Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus. Hum Mol Genet 24(20): 5880-5890.
16. Jearawiriyapaisarn N, Moulton HM, Sazani P, Kole R, Willis MS (2010) Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. Cardiovasc Res 85(3):444-453.
17. Wu B, et al. (2008) Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA 105(39):14814-14819.
18. Jearawiriyapaisarn N, et al. (2008) Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 16(9):1624-1629.
19. Crisp A, et al. (2011) Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. Hum Mol Genet 20(3):413-421.
20. Willmann R, Possekel S, Dubach-Powell J, Meier T, Ruegg MA (2009) Mammalian animal models for Duchenne muscular dystrophy. Neuromuscul Disord 19(4):241-249.
21. Yugeta N, et al. (2006) Cardiac involvement in Beagle-based canine X-linked muscular dystrophy in Japan (CXMDJ): Electrocardiographic, echocardiographic, and morphologic studies. BMC Cardiovasc Disord 6:47.
22. Urasawa N, et al. (2008) Selective vacuolar degeneration in dystrophin-deficient canine Purkinje fibers despite preservation of dystrophin-associated proteins with overexpression of Dp71. Circulation 117(19):2437-2448.
23. Sanyal SK, Johnson WW (1982) Cardiac conduction abnormalities in children with Duchenne's progressive muscular dystrophy: Electrocardiographic features and morphologic correlates. Circulation 66(4):853-863.
24. Nomura H, Hizawa K (1982) Histopathological study of the conduction system of the heart in Duchenne progressive muscular dystrophy. Acta Pathol Jpn 32(6):1027-1033.
25. Moise NS, et al. (1991) Duchenne's cardiomyopathy in a canine model: Electrocardiographic and echocardiographic studies. J Am Coll Cardiol 17(3):812-820.
26. Finsterer J, Stöllberger C (2003) The heart in human dystrophinopathies. Cardiology 99(1):1-19.
27. Spurney CF (2011) Cardiomyopathy of Duchenne muscular dystrophy: Current understanding and future directions. Muscle Nerve 44(1):8-19.
28. Crippa L, Ferro E, Melloni E, Brambilla P, Cavalletti E (1992) Echocardiographic parameters and indices in the normal beagle dog. Lab Anim 26(3):190-195.
29. Braun JP, Benard P, Burgat V, Rico AG (1983) Gamma glutamyl transferase in domestic animals. Vet Res Commun 6(2):77-90.
30. Nigro G, Comi LI, Politano L, Bain RJ (1990) The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 26(3):271-277.
31. Yanagisawa A, et al. (1992) The prevalence and prognostic significance of arrhythmias in Duchenne type muscular dystrophy. Am Heart J 124(5):1244-1250.
32. Wu B, et al. (2011) One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice. Molecular Ther 19(3): 576-583.
33. Wu B, et al. (2012) Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino. Am J Pathol 181(2):392-400.
34. Moulton HM, Moulton JD (2010) Morpholinos and their peptide conjugates: Therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta 1798(12):2296-2303.
35. Amantana A, et al. (2007) Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug Chem 18(4): 1325-1331.
36. Betts C, et al. (2012) Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment. Mol Ther Nucleic Acids 1:e38.
37. Yokota T, et al. (2012) Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther 22(5):306-315.
38. Hayashita-Kinoh H, et al. (2015) Intra-amniotic rAAV-mediated microdystrophin gene transfer improves canine X-linked muscular dystrophy and may induce immune tolerance. Mol Ther 23(4):627-37.
39. Echigoya Y, et al. (2015) Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. Mol Ther Nucleic Acids 4:e225.
40. Hally AD (1964) A counting method for measuring the volumes of tissue components in microscopical sections. J Cell Sci s3(105):503-517.
41. Burki U, et al. (2015) Development and application of an ultrasensitive hybridizationbased ELISA method for the determination of peptide-conjugated phosphorodiamidate morpholino oligonucleotides. Nucleic Acid Ther 25(5):275-284.
42. Osborne BE, Leach GD (1971) The beagle electrocardiogram. Food Cosmet Toxicol 9(6):857-864.
43. Matsuzawa T, Nomura M, Unno T (1993) Clinical pathology reference ranges of laboratory animals. Working Group II, Nonclinical Safety Evaluation Subcommittee of the Japan Pharmaceutical Manufacturers Association. J Vet Med Sci 55(3):351-362.
44. Wolford ST, et al. (1986) Reference range data base for serum chemistry and hematology values in laboratory animals. J Toxicol Environ Health 18(2):161-188.
45. Aiello SE, Moses MA (2016) The Merck Veterinary Manual, Online Edition (Merck, Kenilworth, NJ).